This article is more than 5 years old. Information may no longer be current.

Highly read SLE research articles include EULAR presentations

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The most highly read articles about research in systemic lupus erythematosus this month were largely from research presented at the European League Against Rheumatism Annual European Congress of Rheumatology, held from June 10 to 13 in Rome.

Topics of interest to Healio.com/Rheumatology readers related to systemic lupus erythematosus (SLE) included thyroid dysfunction, kidney involvement and medications that have presented mixed results to researchers.

Thyroid dysfunction common in patients with SLE

Patients with SLE were more likely to have thyroid dysfunction compared with healthy adults, according to a study. Read more.

Anti-Sm may predict need for immunosuppressant therapy in patients with lupus nephritis

Patients with SLE were more likely to have thyroid dysfunction compared with healthy adults, according to recently published research.

AMG-811 shows mixed results in patients with SLE in phase 1 study

Amgen’s experimental AMG-811 may lower serum CXCL-10 and interferon-gamma-modulated mRNA levels in patients with SLE and lupus nephritis, according to recently presented data. Read more.

Edratide produces mixed results following phase 2 trial in patients with SLE

Results from a phase 2 trial of edratide in patients with SLE showed tolerability and clinically significant effects in some patients but failed to meet its primary endpoints, according to a report. Read more.

UCB announces epratuzumab fails to meet endpoint in phase 3 SLE trials

Epratuzumab did not meet its primary efficacy endpoint in two phase 3 trials in patients with SLE, according to a press release from UCB. Read more.

Men with SLE may have higher renal involvement, disease activity and damage vs. women

Men with SLE were more likely to have renal involvement, higher disease activity, accrual of organ damage and higher mortality compared with women with the disease, according to research in a Mexican population. Read more.